Phibro Animal Health (NASDAQ:PAHC) Posts Earnings Results, Beats Estimates By $0.04 EPS

Phibro Animal Health (NASDAQ:PAHC) issued its quarterly earnings results on Wednesday. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04, FiscalAI reports. The business had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%. Phibro Animal Health updated its FY 2026 guidance to 2.980-3.100 EPS.

Phibro Animal Health Stock Performance

Shares of PAHC traded up $2.26 during trading hours on Wednesday, reaching $58.50. 300,750 shares of the company traded hands, compared to its average volume of 260,342. Phibro Animal Health has a 12-month low of $19.00 and a 12-month high of $60.08. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The stock has a market capitalization of $2.37 billion, a P/E ratio of 26.00, a P/E/G ratio of 0.86 and a beta of 0.61. The business has a fifty day moving average price of $54.07 and a 200-day moving average price of $46.48.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be issued a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.8%. Phibro Animal Health’s payout ratio is 21.33%.

Key Stories Impacting Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Quarterly results beat: Phibro reported $0.76 EPS vs. $0.72 expected and revenue of $383.5M vs. $367.0M expected, with net income and sales up year-over-year — a near-term catalyst supporting the stock. Business Wire: Q3 Results
• Positive Sentiment: Dividend declared: Board approved a quarterly cash dividend of $0.12 per share (record June 3, payable June 24), which supports income-focused holders and signals management confidence in cash flow. Press Release / Dividend
• Positive Sentiment: Expanded credit facility: Management expanded the revolving credit facility to bolster liquidity — a near-term positive for financial flexibility and capital allocation. Yahoo: Revolving Credit Facility
• Neutral Sentiment: FY2026 guidance largely in line with Street: Management set EPS guidance of $2.98–$3.10 (consensus ~3.03) and revenue guidance about $1.5B — the midpoint is roughly consistent with analyst expectations, so guidance neither materially raised nor cut. Yahoo: Guidance
• Neutral Sentiment: Sustainability platform launch: Company introduced a companywide sustainable solutions platform and a VERRATAIN™ offering via partnership — positive for long-term ESG positioning but unlikely to be an immediate earnings driver. 01net: Sustainability Platform

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research report on Friday, February 6th. Citigroup initiated coverage on Phibro Animal Health in a research report on Wednesday, April 15th. They set a “neutral” rating and a $62.00 price target on the stock. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Phibro Animal Health has an average rating of “Hold” and a consensus price target of $42.40.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $52.76, for a total value of $371,430.40. Following the sale, the chief executive officer directly owned 74,760 shares of the company’s stock, valued at approximately $3,944,337.60. This represents a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 281,600 shares of company stock valued at $14,334,853 over the last 90 days. 50.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after purchasing an additional 363 shares during the last quarter. Brooklyn Investment Group boosted its holdings in Phibro Animal Health by 8.7% in the fourth quarter. Brooklyn Investment Group now owns 6,757 shares of the company’s stock valued at $255,000 after purchasing an additional 538 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares during the last quarter. Intech Investment Management LLC boosted its holdings in Phibro Animal Health by 8.2% in the third quarter. Intech Investment Management LLC now owns 9,147 shares of the company’s stock valued at $370,000 after purchasing an additional 697 shares during the last quarter. Finally, Swiss National Bank raised its position in shares of Phibro Animal Health by 1.8% in the fourth quarter. Swiss National Bank now owns 40,100 shares of the company’s stock worth $1,498,000 after acquiring an additional 700 shares during the period. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.